Literature DB >> 18536788

Metformin: a review.

Tomas Strack1.   

Abstract

Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its well-established effects on glucose metabolism and, as more recently demonstrated, its benefits on other cardiovascular risk factors. Unlike insulin and secretagogues, metformin does not increase body weight and when used as monotherapy does not likely cause hypoglycemia. The most common adverse effects associated with metformin are mild, transient gastrointestinal symptoms, which are usually self-limiting. These side effects can be minimized by initiating metformin therapy at a low dose and gradually titrating upward, and by taking metformin with meals. Lactic acidosis caused by metformin is rare, and the risk of this complication may be diminished by the observance of prescribing precautions and contraindications that avoid accumulation of metformin or lactate in the body. The many clinical benefits and the lack of safety risks when used with other antihyperglycemic agents have made metformin a preferred combination drug with other oral agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536788     DOI: 10.1358/dot.2008.44.4.1138124

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  11 in total

1.  Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.

Authors:  Konstantin Tsoyi; Hwa Jin Jang; Irina Tsoy Nizamutdinova; Young Min Kim; Young Soo Lee; Hye Jung Kim; Han Geuk Seo; Jae Heun Lee; Ki Churl Chang
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 2.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 3.  Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.

Authors:  Mehrul Hasnain; W Victor R Vieweg; Sonja K Fredrickson
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

4.  Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis.

Authors:  Narender Nath; Musfiquidin Khan; Manjeet K Paintlia; Inderjit Singh; Md Nasrul Hoda; Shailendra Giri
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 5.  Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy.

Authors:  Antonio Desmond McCarthy; Ana María Cortizo; Claudia Sedlinsky
Journal:  World J Diabetes       Date:  2016-03-25

6.  Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.

Authors:  H G Shertzer; E L Kendig; H A Nasrallah; E Johansson; M B Genter
Journal:  Int J Obes (Lond)       Date:  2010-01-12       Impact factor: 5.095

7.  Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice.

Authors:  Vladimir N Anisimov; Tatiana S Piskunova; Irina G Popovich; Mark A Zabezhinski; Margarita L Tyndyk; Peter A Egormin; Maria V Yurova; Svetlana V Rosenfeld; Anna V Semenchenko; Irina G Kovalenko; Tatiana E Poroshina; Lev M Berstein
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

8.  Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells.

Authors:  Rubem R Amador; João Paulo Figueiró Longo; Zulmira G Lacava; José G Dórea; Maria de Fátima M Almeida Santos
Journal:  Genet Mol Biol       Date:  2011-12-15       Impact factor: 1.771

9.  Metformin treatment in hyperglycemic critically ill patients: another challenge on the control of adverse outcomes.

Authors:  Yunes Panahi; Mojtaba Mojtahedzadeh; Nuria Zekeri; Fatemeh Beiraghdar; Mohammad-Reza Khajavi; Arezo Ahmadi
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

10.  Biguanides enhance antifungal activity against Candida glabrata.

Authors:  Shuying Xu; Marianela Feliu; Allison K Lord; Daniel P Lukason; Paige E Negoro; Nida S Khan; Zeina Dagher; Michael B Feldman; Jennifer L Reedy; Samantha N Steiger; Jenny M Tam; Alexander A Soukas; David B Sykes; Michael K Mansour
Journal:  Virulence       Date:  2018       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.